Pretreatment with lidoflazine, a calcium-channel blocker. Useful adjunct to heterogeneous cold potassium cardioplegia.
Ten mongrel dogs were studied to determine if pretreatment with lidoflazine would protect the canine myocardium during aortic cross-clamping when circumflex coronary artery occlusion limits the distribution of cold potassium cardioplegia. A canine right heart bypass preparation was used. Regional function was determined with a sonomicrometer. Twenty minutes before aortic cross-clamping, lidoflazine or solvent was administered in a random, blind fashion. A circumflex artery snare prevented the cardioplegic solution from entering the circumflex artery. A 100 minute arrest period with cardioplegic infusion every 20 minutes was followed by 45 minutes of reperfusion before global and regional function were reevaluated. In the group receiving solvent, postarrest function in the circumflex region recovered to only 30% of prearrest values (p less than 0.05), a marked functional deterioration. In the group protected by lidoflazine, function in the circumflex region returned to 90% of prearrest values (NS). Function in the left anterior descending (LAD) regions of both groups demonstrated full recovery after arrest. Global left ventricular function was well preserved in both groups and failed to reflect the damaged, malfunctioning region in the group receiving solvent. These findings suggest that pretreatment with lidoflazine can improve myocardial protection when delivery of cardioplegia is not homogeneous.
D000818:Animals; D001011:Aorta / Q000601:surgery; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002122:Calcium Chloride / Q000494:pharmacology; D009202:Cardiomyopathies / Q000517:prevention & control; D002315:Cardiopulmonary Bypass; D002319:Cardiovascular System / Q000187:drug effects; D003080:Cold Temperature; D003250:Constriction; D004285:Dogs; D005260:Female; D006321:Heart / Q000502:physiology; D006324:Heart Arrest, Induced; D006352:Heart Ventricles; D008013:Lidoflazine / Q000627:therapeutic use*; D008297:Male; D009206:Myocardium / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use*; D011188:Potassium / Q000627:therapeutic use*; D011292:Premedication; D011300:Preoperative Care
D002121:Calcium Channel Blockers; D010879:Piperazines; D008013:Lidoflazine; D002122:Calcium Chloride; D011188:Potassium